Navigation Links
Public Citizen Petitions FDA to Ban Diabetes Drug Avandia, According to Avandia Plaintiffs Attorney Group

National non-profit organization documents upsurge in negative clinical data associated with use of Avandia, urges FDA commissioner to remove drug from U.S. market immediately

Mineola, N.Y. (Lexis Nexis) November 6, 2008 -- Public Citizen, a non-profit organization representing more than 80,000 consumers nationwide, has petitioned the Commissioner of the U.S. Food and Drug Administration to immediately ban the diabetes drug Avandia, according to Marc Grossman, a member of the Avandia Plaintiffs Steering Committee.

According to the petition, recent clinical studies documented that Avandia has caused an increased risk of heart attacks, heart failure, bone fractures, anemia and retinal edema with vision loss. Perhaps most seriously, the group analyzed 14 cases of liver failure in patients who were taking Avandia, 12 of which resulted in death.

"In the past year, there were 4.6 million (Avandia) prescriptions filled, thus exposing hundreds of thousands of people with diabetes to a drug that is clearly doing more harm than good," according to the Public Citizen petition. "Thus, it is urgent for the FDA to immediately ban rosiglitazone (Avandia)."

The Avandia Plaintiffs Steering Committee has been tracking the reports of multiple serious side effects from Avandia for the past year and represents a number of plaintiffs in litigation against the manufacturer of the drug, GlaxoSmithKline. Many nationwide lawsuits have been centralized in Federal court in the Eastern District of Pennsylvania in front of Hon. Cynthia Rufe, (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, 2:07-md-01871-CMR). This litigation involves thousands of claims for injuries ranging from death and heart attack to vision loss and bone fractures.

"The Public Citizen petition, along with prior recommendations against the use of Avandia from both the American Diabetes Association and the European Association for the Study of Diabetes, is certainly a step in the right direction," said Vance Andrus, lead counsel for the Avandia Plaintiffs Steering Committee. "Many doctors and patients were led to believe that this was a safe and effective drug and, as a result, their lives were put in danger."

Any adverse reactions experienced with the use of Avandia should be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. International Medical Corps Continues Delivering Emergency Relief in Democratic Republic of Congo as Potential for Renewed Fighting Threatens to Deepen Crisis
2. Media Affects Public Perception of Infectious Diseases
3. International Medical Corps Continues Delivering Emergency Relief Amid Violence in Democratic Republic of Congo
4. Evolution Physical Therapy First Clinic in Southern California to Introduce NASA-Designed Anti-Gravity Treadmill for Public Use
5. NQF Endorses Guidelines for Consumer-Focused Public Reporting
6. Teach For America and Lilly Launch Program to Match Lilly Employees with Teachers in Underserved Public Schools
7. ASPH and APHA Collaborate to Shore up the Public Health Workforce Pipeline:
8. Home Health Leaders Launch Alliance to Sponsor Research and to Educate Public and Policymakers on Sectors Contributions to National Health Reform
9. Gather and Harvard Health Publications Launch New Programs to Bring Harvard Medical School Doctors Expertise Online
10. Bloomberg School of Public Health to lead nationwide aging study
11. New State Public Health Department Survey Results Highlight Available Resources for Men and Women
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... GKhair & Tibolli ... the San Juan Beauty Show held on November 8th and 9th at the Puerto ... media personalities, hair artists, renowned beauticians and top of the line fashion journalists. The ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... provider of enterprise Time and Attendance/Workforce Management cloud-based solutions, announced today that ... Program with competencies in the Application Development, demonstrating a “best-in-class” ability and ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... Inc. are pleased to announce their strategic partnership at the Radiological Society ... Transcription Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... product dealer. Joining more than 30 HealthPostures’ dealers located throughout the United States, ... increase the number of corporate, industrial, manufacturing and government workers and organizational leaders ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... patented products, announces the Unstoppable Swappables, a household invention that provides an economical ... $2 billion a year and is growing at 2.6%," says Scott Cooper, CEO ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... DUBLIN , Nov. 27, 2015 Research ... of the "Global Intrauterine Devices Market 2015-2019" ... --> In this report, the author ... intrauterine devices market for 2015-2019. To calculate the market ... of following type of products: Hormonal IUDs and copper ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... November 26, 2015 ... nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie ... ) --> ... (Photo: ) ... Medisch Centrum (LUMC) blijkt ...
Breaking Medicine Technology: